The deal gives Ipsen access to Arix’ network of professional and scientific advisors, and the chance to invest in the firm’s new and existing businesses.
Arix secures partnership with Ipsen
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing Sites in San Diego and Bristol
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.
Batavia Biosciences Expands its Viral Vector and GMP Facilities to Accommodate Increasing Market Demand
Batavia Biosciences announces the expansion of its viral vector process development facilities in the USA and its GMP clean room facilities in the Netherlands to accommodate the increasing market demand.
Commercial Manufacturing Agreement With US WorldMeds For Lofexidine Signed By Catalent
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products announced it has entered into an exclusive agreement with US WorldMeds, LLC for the commercial manufacture of lofexidine.
Orchard Therapeutics Announces Expansion of Technical Operations in California
Orchard Therapeutics , a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, announced the opening of a second facility for technical operations in the San Francisco Bay Area.
Recipharm and Kancera collaborate to manufacture clinical trial supply
Recipharm, a leading contract development and manufacturing organisation (CDMO) and Kancera, a development company focused on cancer therapy, have signed a contract for the development and manufacture of the pharmaceutical candidate KAND567.
Acasti Pharma and CordenPharma Announce Large Scale Production of CaPrewith New Manufacturing Process
Acasti Pharma Inc announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s omega-3 pharmaceutical product candidate, produced with a proprietary and innovative continuous manufacturing process developed in partnership with CordenPharma.